The historic rise of Viagra has long been a benchmark of pharmaceutical success, but its legacy within the broader market now presents questions about long-term returns . Generic versions are diminishing patent protection , causing anxieties that betting on companies significantly dependent to Viagra's previous standing could be a problematic move